All Articles

A new report reveals a dramatic rise in sophisticated cyberattacks fueled by artificial intelligence. Experts warn of a growing leadership awareness gap and a shift towards cybersecurity resilience.

A substantial funding round positions Olema Oncology for growth, validating the potential of its novel breast cancer therapies and benefiting from positive momentum in the SERD market.

Positive Phase 3 trial data signals potential for EyePoint Pharmaceuticals’ DURAVYU to revolutionize wet AMD treatment, offering patients a less frequent alternative to monthly injections and a significant market opportunity.

Rejuva Fresh receives expanded CE certification for its EMSTRONG platform, broadening its application beyond urinary incontinence to include treatment for sexual dysfunction. The company is poised to benefit from the growing ‘intimate wellness’ market.

The renewable energy company’s debt maneuvers, including a $750M bond offering, aim to optimize its capital structure and fund continued expansion despite a challenging market. Investors watch closely.

As Black Friday approaches, Wayfair is doubling down on verified deals and a vast selection, aiming to capture a slice of the booming home goods market. But can its strategy compete with Amazon and other retail giants?

As Canada's cannabis sector matures, Grow Up Vancouver 2026 will tackle critical issues of consolidation, technological advancements, and regional opportunities, shaping the future of the industry.

Positive PFS results for the Cactus Project highlight potential for low-cost production and a significant contribution to domestic copper supply amid growing demand for critical minerals.

European approval of a subcutaneous formulation of Keytruda promises faster, more flexible treatment for cancer patients. This move positions Merck as a leader in innovative drug delivery and expands access to a critical therapy.

La Mancha’s increased investment in Belo Sun Mining Corp. raises questions about potential takeover bids and the future of the Volta Grande Gold Project in Brazil. Is this a strategic play or a precursor to a larger consolidation?

Digital freight platform Freightos partners with regional carrier Pattaya Airways to streamline air cargo booking in Southeast Asia. The move aims to boost efficiency and capacity on key routes like Bangkok-Ho Chi Minh City.

Biotech firm Cellectis unveils promising non-viral gene editing process with significantly improved efficiency. Experts believe this technology could lower costs and broaden access to life-saving therapies.

Global telematics leader Ituran marks three decades of growth and innovation, expanding from vehicle recovery to a data-driven future in fleet management, insurance, and connected car services. The company is poised for further expansion and advancement.

Positive Phase 3 results for Agios' mitapivat in sickle cell disease are tempered by a lack of statistical significance in pain crisis reduction. Analysts weigh the implications for the rare disease drug developer.

A strategic partnership allows Scynexis to prioritize pipeline assets while GSK aims to revive a struggling antifungal, signaling a changing landscape in biotech commercialization.

Allison Transmission's acquisition of Dana's Off-Highway business for $2.7 billion reshapes the off-highway vehicle market, bolstering Allison’s portfolio and prompting strategic shifts for competitors. The deal signals a focus on electrification and expansion.

Dana's divestiture of its Off-Highway business to Allison Transmission signals a strategic shift within the industry, driving consolidation and accelerating the adoption of electric and autonomous technologies.

Strategic partnership with LPL Financial fuels Prudential’s growth, tapping into a significant segment of mass affluent individuals currently without financial guidance. Is this the key to unlocking a massive opportunity?

Positive Phase 3 data for Merck's DOR/ISL offers a simplified HIV treatment option, but past safety concerns and a competitive landscape demand careful scrutiny as it nears FDA review.

With promising late-stage data anticipated in early 2026, Theravance Biopharma is actively engaging investors, highlighting its pipeline and improved financial footing. Focus is on a potential breakthrough for Multiple System Atrophy.